Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGAIN: Osimertinib plus infliximab in EGFR-mutant NSCLC with TP53 gain-of-function after acquired resistance to osimertinib
jRCT2071250017Phase 2Recruiting
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and infliximab in non-small cell lung cancer (NSCLC). Primary endpoint: Objective response rate. Started Oct 2025; status: recruiting.
02
Drugs
osimertinibinfliximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071250017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250017.